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Receptor binding and degradation of urokinase-type plasminogen
activator by human mesangial cells. The binding of [125!] labeled uroki-
nase-type plasminogen activator (u-PA) was studied on human mesan-
gial cells (MC) in culture. The binding of active ['251]u-PA at 37°C
reached a plateau after 30 minutes of incubation and remained stable for
at least four hours. When the supernatant was analyzed with tn-
chioracetic acid (TCA), TCA soluble radioactive material could be
detected after a lag phase of 30 minutes, and then increased linearly for
four hours. Analysis by electrophoresis on SDS PAGE and autoradiog-
raphy of the cell associated radioactivity and of the intracellular content
showed that active u-PA and u-PA complexed to plasminogen activator
inhibitor type-l (PAl-i) were bound to the cell surface, but only
u-PA/PAI-l complexes were internalized and degraded. Therefore, the
Kd and the number of binding sites were determined by competitive
inhibition curves at 4°C using diisopropyl-fluorophosphate (DFP) u-PA.
Scatchard plots showed a Kd = 400 30 p, and Bmax = 240,000
25,000 sites/cell. Excess of the amino terminal fragment of u-PA (ATF)
completely blocked the specific binding of ['251]u-PA, confirming that
the binding of u-PA was independent of the presence of the active site
and/or of the formation of complexes with PAl-i. 3H thymidine
incorporation by mesangial cells after stimulation with 100 nM active
u-PA showed that u-PA had a moderate but significant mitogenic effect,
in contrast to inactive u-PA and ATF. However, this mitogenic effect
was not accompanied by a proliferative effect. Pretreatment of mesan-
gial cell with a phosphoinositol-specific phospholipase C decreased the
binding of ['251]u-PA by 60%, indicating that the majority of the u-PA
receptor is anchored in the membrane by a phosphatidylinositol group.
These results, together with a positive labeling of MC with monoclonal
antibodies to the receptor of U937 cells, and the positive RNA
hybridization with the cDNA probe for the human receptor cloned from
U937 cells, indicate that the u-PA receptor on mesangial cells is
identical to the one of U937 cells. In conclusion, human mesangial cells
in culture express a specific receptor for u-PA, which could play a major
role in the regulation of u-PA activity by degrading u-PA complexed to
PAl-i.
The existence of a fibrinolytic activity in the human glomer-
ulus is well documented [1, 2], and this activity is found in
glomerular cells in culture. Visceral epithelial cells synthesize
and secrete mainly free urokinase-type plasminogen activator
(u-PA) in its zymogen form, and very few tissue-type plasmin-
ogen activator (t-PA), which is entirely complexed to plasmin-
ogen activator inhibitor type-i (PAl-i) [3, 4]. The type of
Received for publication October 6, 1993
and in revised form January 21, 1994
Accepted for publication January 24, 1994
© 1994 by the International Society of Nephrology
plasminogen activators secreted by mesangial cells is still a
matter of debate. Our group has previously demonstrated the
secretion of t-PA and a large excess of PAl-i exclusively [5],
whereas others have recently reported the secretion of u-PA
[6], and even of plasminogen activator inhibitor type-2 [7].
Whatever the type of PA secreted, one efficient way to focalize
PA proteolytic activity at cell to cell contact and cell to
basement membrane interface is by mean of receptors. Specific
receptors for t-PA have been reported essentially on endothelial
cells [8, 9], but the most widely studied has been the u-PA
receptor [reviewed in 10]. Because of the prominent role of the
u-PA receptor in extracellular matrix turnover, we asked
whether mesangial cells, which do not synthesize u-PA protein,
would possess a receptor for u-PA that could bind u-PA
secreted from either glomerular endothelial cells [11] or by
infiltrating macrophages. Our results extend the observation
made in a recent paper of binding sites for u-PA on human
mesangial cells in culture [6] and show the existence of a
specific receptor identical to the one originally described on
U937 cells [12]. In addition, we show that the binding of u-PA
to its surface receptor can induce a mitogenic effect, and the
activity of bound u-PA can be down-regulated by the internal-
ization and degradation of u-PA complexed to PAl-i secreted
by mesangial cells.
Methods
Reagents
[125J] was from NEN Dupont de Nemours (Boston, Massa-
chusetts, USA). High molecular weight urokinase-type plas-
minogen activator (u-PA) was obtained from Serono (Coinsins,
Switzerland) and the amino terminal fragment of u-PA (ATF)
[13] was a gift from Dr. P.A. Marcotte (Abbott Laboratories,
Chicago, Illinois, USA). Monoclonal antibody to the urokinase
receptor was provided by Dr. K. DanØ (Finsen Laboratory,
Rigshospitalet, Copenhagen, Denmark). Monoclonal antibody
to CD3 1, a surface antigen specific of endothelial cells (DAKO-
CD31, JC/70A) was obtained from Dakopatts (Glostrup, Den-
mark). Biotinylated anti-mouse IgG was from Vector (Burlin-
game, California, USA), gold labeled streptavidine was from
Sigma (St. Louis, Missouri, USA), and the silver enhancement
reagent was from Biocell (Cardiff, UK). Phosphatidylinositol-
specific phospholipase C (PT-PLC), diisopropyl-fluorophos-
phate (DFP) and phorbol l2-myristate 13-acetate (PMA) were
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purchased from Sigma. Sephadex G 25 columns were from
Pharmacia (Upsala, Sweden). RPMI 1640,fetal calf serum were
from GIBCO (Grand Island, New York, USA), and L-glu-
tamine was from BioMérieux (Asnières, France). All other
reagents were of analytical grade.
DFP inactivation of u-PA
The active site of u-PA was blocked by incubation with 20
mM DFP (DFP-u-PA) for one hour at 37°C and then extensively
dialyzed in phosphate buffer saline (PBS, sodium phosphate
0.1 M, pH 7.4) containing 0.1% Tween 20. About 95% of the
enzyme was inactivated as judged by SDS polyacrylamide gel
electrophoresis followed by zymography on fibrin plates [14].
Protein labeling
u-PA, DFP-u-PA and ATF were labeled by the IODO-GEN
method [15] to specific activities of 0.5 pCi/pmol for u-PA and
DFP-u-PA and 0.2 pCilpmol for ATF. Briefly, 1 mCi ['251]-Na
was allowed to react with 50 jg IODO-GEN before the addition
of 50 jg of u-PA, DFP-u-PA or ATF, and the mixture was kept
on ice for 30 minutes. Free [1251] was separated from labeled
PAs on a Sephadex G 25 column saturated with bovine serum
albumin, and extensively washed with 50 mt Tris-HC1 buffer
pH 7.5, containing 100 mrs NaC1 and 0.1% Tween 20.
Cell culture
Primary culture of human mesangial (MC) obtained from a
kidney unsuitable for transplantation was established as previ-
ously reported [5]. The cells were characterized by their large
and stellate morphological aspect in contrast phase microscopy,
a positive immunofluorescence staining with alpha-smooth
muscle cell actin antibody (gift from Dr. G. Gabbiani, Depart-
ment of Pathology, Geneva, Switzerland), negative staining
with von Willebrand factor (F8/86, Dakopatts, Denmark) and
with cytokeratin (RPN 1163, Amersham, UK) monoclonal
antibodies. The cells were maintained in RPMI supplemented
with 10% heat-inactivated fetal calf serum and containing 2 mM
L-glutamine. Visceral epithelial cells were obtained and cul-
tured as described [4]. U937 cells, a gift from Dr. E.K.O.
Kruithof (Laboratoire Central d'Hdmatologie, CHUV, Lau-
sanne, Switzerland), were cultured in RPMI 1640 containing
10% fetal call serum and 2 mrt L-glutamine. Prior to total RNA
extraction, the U937 cells were stimulated with 150 nM PMA for
24 hours [16].
Binding of labeled PAs to the cells
All binding experiments were done between passes 4 and 7
with cells grown on 12- or 24-well culture plates. The cells were
incubated either at 37°C or at 4°C, with ['251]PA in 1 ml PBS
containing 1% bovine serum albumin (PBS/BSA), in the pres-
ence or in the absence of competitors. At the end of the
incubation time, the supernatant was discarded, the cells were
washed twice with 1 ml ice-cold PBS, lysed with 1 ml NaOH
1 M, and the cell associated radioactivity counted in a gamma
counter. In some experiments the cells were washed in PBS and
acid treated [17] in order to remove potentially bound u-PA
prior to the binding assays. Briefly, the cells were incubated for
three minutes at room temperature with 1 ml glycin buffer
(50 mM glycin, 100 mri NaCl, pH 3), then quickly neutralized
with 0.5 ml of HEPES buffer (500 mrt HEPES, 100 mM NaCl,
pH 7.4), and washed twice with 1 ml PBS. To study whether
the u-PA receptor was anchored by a glycosyl phosphatidylino-
sitol group, mesangial cells were pretreated for four hours at
37°C with increasing amounts of P1-PLC before measuring
[12511DFP-u-PA binding.
Internalization and degradation of['251]PAs
Mesangial cells grown in 12-well culture plates were incu-
bated at 37°C with 1 ml PBS/BSA containing 100 M ['251]PA, in
the presence or the absence of 10 flM cold u-PA. At intervals,
the supernatant was drawn and treated with trichloracetic acid
(TCA) 10% final concentration, for 30 minutes at 4°C. TCA
precipitable and soluble materials were separated by centrifu-
gation for 15 minutes at 15,000 g and counted. The cell
associated radioactivity was counted after addition of 1 ml
NaOH 1 M. To study the molecular state of active [1251]u-PA
during the incubation, aliquots of the supematants, of the cell
surface-associated radioactivity removable by acid treatment,
and of the intracellular content obtained by lysis with PBS
Triton XlOO 0.1%, were analyzed by electrophoresis on a 10%
SDS polyacrylamide gel, and the gels dried before exposure to
X-ray film at —70°C. In comparison to u-PA, similar analysis of
the molecular forms of ['251]ATF during the incubation with the
mesangial cells was also made and analyzed on a 14% SDS
polyacrylamide gel.
Determination of the dissociation constant and of the number
of binding sites
The Kd and the number of binding sites (Bmax) were calcu-
lated from the Scatchard transformation of the competitive
inhibition curves; 5 iO cells per well were incubated with
mixtures of ['251]DFPu-PA (30 pM) and cold u-PA (25 M to 10
nM) for two hours at 4°C. The supernatant was discarded and
the cell associated radioactivity was measured as described.
3H thymidine incorporation
Mesangial cells were grown to confluency in 12-well culture
plates, and serum starved for 24 hours before the addition of
either active u-PA (100 nM), DFP inactivated u-PA (100 nM),
ATF (100 nM), or active human thrombin (10 nM) as a control.
After 24 hours of incubation in the presence of the different
stimulators, 1 sCi 3H thymidine was added and the cells further
incubated for six hours. At the end of the incubation time, the
supernatant was discarded, the cells were detached with tryp-
sin, and cell incorporated radioactivity counted in a 13 counter.
The proliferation of mesangial cells was studied in the presence
of u-PA 100 flM or 10% fetal call serum as control, over a seven
day period, and with fresh medium added every day.
Immuno gold silver staining and epipolarization microscopy
Mesangial cells were cultured to confluency on glass slides,
and fixed on paraformaldehyde 4% in PBS for 30 minutes and
abundantly rinsed in PBS. The cells were incubated with the
monoclonal antibody to the urokinase receptor or with the
monoclonal antibody to CD3I, for 30 minutes at room temper-
ature, washed extensively with PBS, and reincubated with
biotinylated anti-mouse IgG for 30 minutes. After washing,
0.5% gold labeled streptavidin was added, and incubated for 60
minutes. The slides were then washed in distilled water before
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amplification with the silver enhancement reagent for 10 min-
utes, and counterstained with Giemsa. The photographs were
taken with combined brightfield and epipolarization micros-
copy.
Northern blot analyses
Total RNA was extracted from mesangial, epithelial and
U937 cells by the acid guanidium thiocyanate-phenol-chioro-
form method. Twenty micrograms of RNA were separated on a
0.9% denaturing agarose gel, and transferred onto a nylon
membrane (Gene Screen Plus, New England Nuclear). The
membrane was prehybridyzed for four hours at 42°C, and
hybridized with [a-32P]dCTP specific probe for the u-PA recep-
tor (a 1200 bp Barn Hi fragment of human u-PA receptor cDNA
provided by Dr. E.K.O. Kruithof, Laboratoire Central d'Hd-
matologie, CHUV, Lausanne, Switzerland), for 24 hours at
42°C. The filter was washed three times with 2 x SSC buffer
(1 SSC = 0.15 M NaCl, 0.015 M sodium citrate) containing 0.1%
SDS, at 45°C, for 30 minutes, and exposed to X-ray film at
—70°C. Thereafter, the same membrane was dehybridized by
boiling 30 minutes in 2 x SSC, and rehybrized with
[a-32P]dCTP specific probe for the human u-PA (a 600 bp Eco
Ri fragment of human u-PA cDNA provided by Dr. R-L.
Medcalf, Laboratoire Central d'Hdmatologie, CHUV, Lau-
sanne, Switzerland).
Results
Binding and degradation of['251]u-PA to confluent
monolayers of mesangial cells
The binding of [1251]u-PA (Fig. 1A) and of ['25IJDFP-u-PA
(Fig. 1B) at 37°C increased rapidly, reached a plateau after 60
minutes, and remained stable for at least three hours. In the
presence of excess of cold u-PA, the binding of u-PA was
reduced by more than 90%, indicating that the majority of the
binding was specific. When the supernatant was analyzed for
the degradation products, TCA soluble material could be de-
tected in the supernatant of cells incubated with active u-PA
only, after a lag phase of 30 minutes, and increased linearly for
at least four hours, suggesting that active u-PA was degraded
(Fig. 1A). Inhibition of the binding of ['251]u-PA by either
excess of u-PA or excess of ATF completely abolished the
appearance of the TCA soluble material (not shown).
Analysis by SDS-PAGE and autoradiography of the superna-
tant of cells incubated with active ['251]u-PA showed the
presence of two bands, one of Mr 54 kDa corresponding to free
['251}u-PA and one of 95 kDa corresponding to the u-PAIPAI-1
complex (Fig. 2, upper panel, A). The intensity of the 54 kDa
band decreased with time while the intensity of the 95 kDa band
increased, reflecting the increase of complex formation between
u-PA and PAl-i secreted by mesangial cells during the incuba-
tion time. Analysis of the cell surface associated radioactivity
showed the presence of a very faint band of 54 kDa and a
marked band of 95 kDa, the latter increasing in intensity during
the incubation period (Fig. 2, upper panel, B). Analysis of the
intracellular content showed only the presence of the 95 kDa
band, which intensity increased during the time of incubation,
and no band of u-PA alone (Fig. 2, upper panel, C). The
accumulation of radioactive material of low molecular weight in
the migrating front confirmed that u-PA/PA!-! complexes were
degraded. When the analysis by SDS-PAGE was performed
Time, minutes
Fig. 1. Time course of the binding and degradation of ['251Ju-PA by
mesangial cells. iO in 12-well plates were incubated at 37°C with 1 ml
PBS/BSA containing 50 PM ['251)u-PA. Nonspecific binding was deter-
mined in the presence of 10 n cold u-PA. At intervals, the superna-
tants were drawn, and treated with TCA as described in the text. (A)
The experiment performed with active ['251]u-PA and (B) with
['25flDFP-u-PA. Symbols are (•) total binding, () nonspecific binding,
(x) TCA soluble fraction. This figure represents the mean of 2 indepen-
dent experiments performed in duplicate.
using labeled ATF instead of u-PA, the results showed a single
band of ['251]ATF in the supernatant and on the cell surface
(Fig. 2, lower panel, A and B), as expected. The amount of
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Fig. 2. SDS-PAGE and autoradiography analysis of active ['251]u-PA and ['25IJATF incubated with mesangial cells. i0 cells in 12-well plates
were incubated with 100 pa ['251]u-PA or ['251]ATF at 37°C. At intervals, the supernatant was drawn, the cells treated with 0.2 ml glycin buffer
to remove the cell surface associated radioactivity and the cells lysed with 0.2 ml of PBS containing 0.1% Triton X100. The samples were separated
on a 10% SDS-PAGE for u-PA and 14% for ATF, under nonreducing conditions, and subjected to autoradiography. ['25!]u-PA, upper panel;
['251]ATF, lower panel; (A) supernatants, (B) acid extractable radioactivity, (C) intracellular content, analyzed after 30, 60, 120 and 180 minutes
of incubation (the amount of intracellular [25I]ATF was too low to be resolved on the SDS-PAGE). u-PA refers to ['251]u-PA alone and u-PA/PA!-!
refers to ['251]u-PA incubated with purified PA!-!. The molecular weight markers are indicated on the left side.
intracellular radioactive material was neglectible, even after
three hours of incubation, and could not be analyzed by
SDS-PAGE.
All together, these results suggest that u-PA, bound to
mesangial cells receptor via the ATF domain, was still acces-
sible to PAl-i, and that u-PA complexed to PAT-i was internal-
ized and degraded. Subsequently, the characteristics of the
binding of u-PA to mesangial cells were performed at 4°C with
['251]DFP-u-PA.
Characteristics of the binding of u-PA to mesangial cells
The dissociation constants (Kd) and the maximum numbers
of binding sites were determined by Scatchard transformation
of competitive inhibition curves, by incubation of ['25IJDFP-u-
PA in the presence of increasing amounts of cold active u-PA.
Fifty percent inhibition of maximal binding was achieved with
300 M (Fig. 3), and Scatchard plots gave Kd 400 30 p and
Bm = 240,000 25,000 sites/cell (Fig. 3, inset). A Scatchard
plot calculated from saturation curves by using increasing
amounts of labeled u-PA showed a Kd of 425 p, and 150,000
binding sites per cell (data not shown). Pretreatment of mesan-
gial cells with acid buffer in order to dissociate potential
endogenous u-PA bound to the cell surface did not modify
[1251]DFP-u-PA binding. ATF, which represents the 135 first
amino acids of the u-PA molecule, inhibited ['251]DFP-u-PA
binding to the same extent that u-PA, but excess of tissue-type
plasminogen activator, another serine protease with high struc-
tural homology to u-PA, had no effect (Fig. 4). These results
confirms that u-PA binding does not depend on the active site
and/or the interaction with PAl-i. The binding of ['25IJDFP-u-
PA was very slowly reversible (Fig. 5).
P1-PLC treatment of the u-PA receptor
The u-PA receptor on U937 cells was reported to be anchored
in the membrane via a glycosyl-phosphatidylinositol group [18].
Therefore, we pretreated the mesangial cells with a phos-
phoinositol-specific phospholipase C before measuring the
binding of ['251]u-PA. The results show that the specific binding
of ['251]u-PA decreased with increasing concentrations of PT-
PLC, and approximately 60% of the specific binding was
abolished with 500 mU/mi PT-PLC (Fig. 6).
3H thymidine incorporation
The results show that incubation of mesangial cells with 100
nM active u-PA (a concentration far above the Kd of 400 p and
which would be sufficient to saturate the receptor capacity)
C
0
.0
0
Fig. 3. Competitive inhibition of['251]DFP-u-
PA binding in the presence of increasing
amounts of u-PA. 5 x iO cells in 24 well
plates were incubated with mixtures of
['251]DFP-u-PA (30 pM) and cold u-PA (25 M
to 10 nM) for 2 hours at 4°C. The supernatants
were discarded, the cells washed twice with 1
ml cold PBS, solubilized with 1 ml NaOH 1
M. Cell associated radioactivity was counted
in a gamma counter. This figure shows one
representative experiment. Inset: Scatchard
100000 transformation of the competitive inhibition
curve yielded Kd = 360 M and Bmax =
220,000 binding sites per cell.
induced a small but significant increase of 3H thymidine incor-
poration (135% increase of 3H thymidine incorporation, P <
0.05). On the contrary, neither 100 flM of DFP-u-PA nor 100 flM
of ATF had significant mitogenic effects on mesangial cells (Fig.
7). This moderate mitogenic effect was not accompanied by a
proliferative effect, since incubation of mesangial cells with 100
n active u-PA during seven days did not increase the number
of cells (25,000 3,000, 24,000 2,500, 60,000 5,000,
cells/well for mesangial cell incubated for 7 days with RPMI
alone, RPMI with 100 n u-PA and RPMI with 10% fetal calf
serum as control, respectively).
Immunogold silver staining (IGSS)
To further characterize the u-PA receptor on mesangial cells,
we have used a monoclonal antibody to the urokinase receptor
purified from U937 cells [19]. The lOSS showed a homogenous
distribution on the cell surface of mesangial cells (Fig. 8a).
Northern blot analysis
Northern blot analysis of mesangial cells RNA with the
specific probe for the human u-PA receptor cDNA showed a
signal in the same position as for u-PA receptor mRNA from
U937 cells stimulated with PMA, but no signal could be
evidenced when the RNA of MC was hybridized with the
human u-PA probe. In contrast, RNA from visceral epithelial
cells studied in parallell showed a hybridization with both u-PA
and u-PA receptor probes (Fig. 9).
Discussion
In this report, we showed that human mesangial cells in
culture possess a high affinity receptor for u-PA (Kd = 400 pM),
and of limited number on the cell surface (240,000 sites per cell).
u-PA in which the active site was blocked by DFP bound to MC
to a similar extent that active u-PA, and the specific binding of
u-PA could be inhibited by excess of the amino terminal
fragment of u-PA, while excess of tissue-type plasminogen
activator did not influence the binding of u-PA. All together,
these results indicate that the binding of u-PA to its receptor
involved the ATF domain of the u-PA molecule, and that the
binding did not depend on the presence of the active site of
u-PA. The appearance in the incubation milieu of trichioracetic
soluble radioactive material when cells were incubated with
active u-PA only, but not with DFP-u-PA, suggests that active
u-PA bound to its receptor was degraded. Analyses of the
molecular state of u-PA during the incubation showed that
surface bound [1251]u-PA was rapidly complexed to PAl-i,
probably secreted by mesangial cells [5], and that u-PA/PAT-I
complexes were internalized and degraded.
These results suggest that either ['251]u-PA bound to its
receptor was still accessible to PAl-i [20] or that the receptor
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Fig. 4. Effects of the amino terminal fragment of u-PA and oft-PA on the
binding of['251Ju-PA. i0 cells in 12 well plates were incubated at 4°C for
2 hours with buffer (D), u-PA 10 nM (•), ATF 10 nM () or t-PA 100 nM() before the addition of ['I]u-PA 50 p, and the incubation was
prolonged for 2 hours. The supernatants were withdrawn, the cells washed
twice with 1 ml of cold PBS and lysed with 1 ml NaOH. The results are
mean SD of 2 independent experiments performed in duplicate.
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Fig. S. Reversilibily of the binding of ['25IJDFP-u-PA. 5 x lO cells in
24 well plates were allowed to bind 30 pri ['251]DFP-u-PA for 2 hours at
4°C. The cells were washed twice with I ml PBS, and reincubated with
1 ml PBS/BSA containing 10 n cold u-PA to prevent reassociation of
['251]DFP-u-PA. At intervals, the supernatant was drawn, and released
radioactivity was counted. The figure represents the mean of 2 inde-
pendent experiments performed in duplicate.
only binds u-PA/PAl-i complexes. Based on the fact that the
binding and the degradation of active u-PA could be blocked by
excess of ATF (that does not bind PAT-i because it lacks the
2000
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Fig. 6. Effect of the pretreatment of mesangial cells by phosphoinosi-
tol-specfic phospholipase C (P1-PLC) on the binding of ['25IJDFP-u-
PA. Mesangial cells in 12 well plates were pretreated with increasing
amounts of P1-PLC for 4 hours at 37°C. After 2 washes with PBSIBSA,
50 M ['251]DFP-u-PA was added and the cells were incubated for 2
hours at 4°C. The supernatants were discarded, and the cell associated
radioactivity counted. The specific binding was measured in the pres-
ence of 10 nM u-PA. Symbols are: no P1-PLC, (0) total and (I)
nonspecific binding; pretreatment with 250 mU/ml P1-PLC, () total
and () nonspecific binding; pretreatment with 500 mU/mi P1-PLC, (0)
total and () nonspecific binding. The results are mean SD of 2
independent experiments performed in duplicate.
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Fig. 7. Mitogenic effect of u-PA, DFP-u-PA and ATF. Mesangial cells
in 12 well plates were serum starved for 24 hours and incubated with
RPMI 1640 alone (U), containing 10 n active human thrombin (a),
activeu-PA 100 nM (0), DFP inactivated u-PA 100 nM (I), or ATF 100
nM (D) for 24 hours. One micro curie of 3H thymidine was then added
and the incubation prolonged for 6 hours. After washing twice with 1 ml
PBS, the cells were trypsinized and the cell-incorporated radioactivity
counted in a /3 scintillation counter. The results are mean SD of 2
independent experiments performed in duplicate. **P < 0.05 as com-
pared to the control.
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Fig. 9. Northern blot analysis of mesangial cells RNA with a specific
probes for u-PA receptor and u-PA. Twenty micrograms of total RNA
from visceral epithelial cells (E), mesangial cells (M), or from U937 cells
stimulated 24 hours with 150 flM PMA (U), were resolved in a 0.9%
agarose gel, transferred on a nitrocellulose membrane and hybridized
with specific probes for human u-PA receptor cDNA (right panel) and
then for human u-PA cDNA (left panel). The filters were exposed for 7
days (u-PA receptor) and 5 days (u-PA). Even loading and the integrity
of total RNA was verified by the coloration of the membrane after
transfer with methylene blue. The sizes of u-PA mRNA (2.5 kb) and
u-PA receptor mRNA (1.4 kb) are indicated on the left, and the
positions of ribosomal RNA are on the right side.
Fig. 8. Labeling of mesangial cells with a monoclonal antibody to the
human u-PA receptor. Mesangial cells grown on a glass slide were fixed
and labeled with (a) a monoclonal antibody to the human u-PA receptor,
or (b) with a monoclonal antibody to CD3 1, as described in the text. The
picture was taken with combined brightfield and epipolarization micros-
copy (Leitz-Orthoplan, Wild Leitz, Heezbrugg, Switzerland). Magnifi-
cation x 900.
active site of u-PA), and that the analysis of the molecular forms
of ATF incubated with mesangial cells showed that ATF
remained associated to the cell surface, but was not internal-
ized, we conclude that surface-bound u-PA was accessible to
and was inhibited by PAl- 1, and then the complex was inter-
nalized and degraded, as already described for U937 cells [211.
Our results suggest that the u-PA receptor on mesangial cells
is identical to the receptor originally purified and cloned from
the human U937 monocyte-like cells and this conclusion is
based on the following: (1) the binding of u-PA to the receptor
is mediated by the amino terminal fragment domain and the
degradation of bound u-PA is dependent on the formation of
u-PAIPAI-l complexes; (2) the receptor on MC is sensitive to
phosphoinositol-specific phospholipase C; (3) the u-PA receptor
mRNA of mesangial cells hybridyzes with a specific probe for
the u-PA receptor cloned from U937 cells [221; (4) mesangial
cells show a positive labeling with a monoclonal antibody
against the u-PA receptor purified from U937 cells.
Since the u-PA molecule possesses an epidermal growth
factor-like domain located in the amino terminal region, and
that u-PA has been shown to have a mitogenic effect on human
visceral epithelial cells [231, we asked whether the binding of
exogenous u-PA to the receptor on mesangial cells would have
mitogenic effects. The results show that active u-PA provokes a
small but significant increase of 3H thymidine incorporation,
but, unlike epithelial cells, u-PA does not induce a proliferation
of mesangial cells. As for epithelial cells, the mitogenic effect of
u-PA requires not only the binding of u-PA to its receptor, but
also the presence of the active site, since neither the amino
terminal fragment of u-PA nor active site-blocked u-PA had a
significant effect. The moderate effect of u-PA could be attrib-
uted to inactivation by PAl-i; however, the rate of synthesis of
PAl-i is far below the amount of added u-PA (100 flM u-PA are
added while approximately 200 nglml, that is, 5flM of PAl-i are
secreted over a 24 hr period) [5]. Therefore, mitogenesis does
not appear to be the essential consequence of the binding of
u-PA to its receptor on mesangial cells.
In recent years, attention has focused on the activation of the
plasminogen/plasmin system at the cell surface, and its role in
the cell to cell, cell to matrix, and cell to basement membrane
interactions. Indeed, plasmin is a trypsin-like serine protease of
broad activity, that has the capacity to degrade fibronectin [24],
laminin [251, collagen IV [26], and can activate procollagenase
and prostromelysin [27]. The cell surface generation of plasmin
is highly favored by the focalization of plasminogen and plas-
minogen activators, mainly u-PA, on the cell membrane by
means of their receptors [28]. Even though mesangial cells do
not synthesize u-PA (Lacave et al [5], and our Northern blot
analyses), the u-PA receptor on mesangial cells could bind in a
paracrine manner pro-u-PA from either glomerular endothelial
uPA
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cells [11] or from resident monocytes-macrophages, inducing
the activation the proteinase cascade, pro-u-PA into u-PA [29],
plasminogen into plasmin, which would in turn activate metal-
loproteinases, as described for rat mesangial cells [30]. There-
fore, the existence of the u-PA receptor could be essential for
the generation of a plasmin activity on the mesangial cell
surface and for the local proteolytic activity and, finally, the
inactivation of surface internalization and degradation of u-PA!
PA!-! complexes would provide an efficient regulation of the
activity of u-PA.
In conclusion, our results show the existence of a specific
receptor for u-PA on human mesangial cells in culture, which
internalize and degrade u-PA/PAI-l complexes. This receptor is
very similar to the u-PA receptor on U937 cells. It remains to be
seen whether u-PA bound to mesangial cells would play a role
in the extracellular matrix degradation.
Reprint requests to G. Nguyen, INSERM U 64, 4 rue de Ia Chine,
75970, Paris, France.
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